← Back

Wire · operational-macro

Next-Gen Anticoagulant Lands FDA Nod for Secondary Stroke Prevention

Published

11 November 2026

Topic

operational-macro

◆ Sectors

Drug Discovery

◆ Geography

United States

◆ Source

Read at medpagetoday.com →

◆ Verified

Fusion42 · 11 November 2026 · Fusion42 review

The FDA granted approval to asundexian (Sunharbo), the first factor XIa inhibitor, for use in secondary stroke prevention. This approval was supported by the OCEANIC-Stroke trial demonstrating its efficacy.

This Wire brief sits within Fusion42's coverage of Drug Discovery, and 15 sources have reported it between 9 Nov 2026 and 19 Nov 2026.

◆ ◆ The Wire takeaway

You have a new competitor setting the standard in stroke prevention with the first factor XIa inhibitor now approved in the US. Consider accelerating development or partnerships if your anticoagulant pipeline lacks this novel mechanism.

◆ Coverage

15 sources · first reported 9 Nov 2026 · latest 19 Nov 2026

◆ Related on Wire

◆ Topics

Drug Discoveryfda-approvalstroke-preventionanticoagulantsdrug-launchclinical-trial